VivoSeq
Other

Common Wart

16

Pipeline Programs↗

1

Active Trials↗

15

Companies Involved↗

Common Wart is an emerging landscape with 16 programs across 15 companies. The most active players are LEO Pharma, Aclaris Therapeutics, Inc., Graceway Pharmaceuticals, LLC. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

92/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

LEO Pharma logo

LEO Pharma

1 program

Phase 1A

Aclaris Therapeutics, Inc.

1 program

Phase 2G

Graceway Pharmaceuticals, LLC

1 program

Phase 2G

G&E Herbal Biotechnology Co., LTD

1 program

Phase 2R

RXi Pharmaceuticals, Corp.

1 program

Phase 2H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

29

clinical trials

Completed24 · 83%
Unknown status2 · 7%
Withdrawn1 · 3%
Not yet recruiting1 · 3%
Suspended1 · 3%

Clinical Trials

Trial Activity

29 trials

Sclerotherapy and Candida Antigen in Treatment of Common Warts
Not yet recruiting·SSohag University·N/A·NCT06749665·75 enrolled
Comparison of Cryotherapy and Peeling Agent in the Treatment of Common Warts
Completed·—·N/A·NCT05712811·60 enrolled
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
Completed·GGraceway Pharmaceuticals, LLC·Phase 2·NCT00116662·84 enrolled
Study of A-101 Topical Solution for the Treatment of Common Warts
Completed·AAclaris Therapeutics, Inc.·Phase 3·NCT03687372·503 enrolled
ALC-919 For The Treatment Of Common Warts
Completed·VVeloce BioPharma LLC·Phase 2·NCT02483455·21 enrolled
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts
Completed·VViroXis Corporation·Phase 2·NCT01286441·183 enrolled
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
Completed·AAclaris Therapeutics, Inc.·Phase 2·NCT03278028·159 enrolled
A Study of A-101 Solution in Subjects With Common Warts.
Completed·AAclaris Therapeutics, Inc.·Phase 2·NCT02669862·98 enrolled
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
Completed·AAclaris Therapeutics, Inc.·Phase 2·NCT03210337·157 enrolled
Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts
Completed·—·Phase 2·NCT02798419·50 enrolled
Intralesional Vitamin D Injection for Treatment of Common Warts
Completed·—·Phase 2·NCT04278573·77 enrolled
Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Completed·NNielsen BioSciences, Inc.·Phase 2·NCT02393417·243 enrolled
A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Completed·MMaruho Co., Ltd.·Phase 3·NCT02971891·484 enrolled
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin
Completed·—·N/A·NCT01084824·70 enrolled
Study With a Topical Gel to Treat Common Warts in Adults
Completed·GGraceway Pharmaceuticals, LLC·Phase 2·NCT00117923·88 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)